BioCentury on BioBusiness,
Analyst Picks & Changes
Analyst picks & changes
Published on
Monday, January 23, 2012
|
Company
|
Bank
|
Analyst
|
Coverage
|
Opinion
|
Wk
chg
|
1/20
cls
|
|
Amgen
Inc. (NASDAQ:AMGN)
|
Baird
|
Christopher
Raymond
|
Price
target
|
Market
outperform
|
3%
|
$69.57
|
|
Raymond
raised his target to $75 from $67 after "very positive" feedback
from a November survey of 98 oncologists indicated that his estimates for
denosumab were too low. The human mAb targeting receptor activator of
NF-kappa B ligand (RANKL) is approved as Prolia in the EU and U.S. to treat
osteoporosis in postmenopausal women and in the EU to treat bone loss
associated with hormone ablation in men with prostate cancer. It is also
approved as Xgeva in the U.S. and EU to prevent skeletal related events in
adults with bone metastases.
|
|
Auxilium
Pharmaceuticals Inc. (NASDAQ:AUXL)
|
RBC
Capital Markets
|
Michael
Yee
|
Upgrade
|
Outperform
(from sector perform)
|
0%
|
$19.90
|
|
Yee
also raised his target to $26 from $20 ahead of Phase III data anticipated
next quarter for Xiaflex collagenase clostridium histolyticum for Peyronie's
disease. Yee models a 70% chance of positive data from the trial, which he
said could drive the stock up to $30. Yee also notes that Auxilium's new CEO,
Adrian Adams, has sold three companies and if the Peyronie's data is
positive, the company would be an attractive takeout. Auxilium has worldwide
rights to the injectable form of collagenase from BioSpecifics
Technologies Corp. (NASDAQ:BSTC).
|
217
words displayed of
697
words total.
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2013 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement and the BioCentury Terms of Use. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions at www.biocentury.com. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
|
Current Subscribers
If you are a current subscriber, log in below or in the upper right corner of this
page.
Log In
Subscription Option
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial 4 Weeks of Access
Get a 4-week free trial subscription to see the important articles you are missing.
Get 4 Weeks Free
Thank You
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
records.
close [ X ]